Cargando…
Bioequivalence Studies of New Generic Formulations of Vildagliptin and Fixed-Drug Combination of Vildagliptin and Metformin Versus Respective Originator Products in Healthy Volunteers
INTRODUCTION: Vildagliptin and metformin are two well-established oral antidiabetics with a complementary mechanism of action. Two new generic products, vildagliptin and its fixed-drug combination (FDC) with metformin, were tested for bioequivalence versus the approved originator reference products...
Autores principales: | Schnaars, Yvonne, Gaikwad, Sumedh, Gottwald-Hostalek, Ulrike, Klingberg, Ulrike, Vadla, Hari Kiran Chary, Prathap, Vamshi Ramana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174400/ https://www.ncbi.nlm.nih.gov/pubmed/35543870 http://dx.doi.org/10.1007/s13300-022-01269-1 |
Ejemplares similares
-
Bioequivalence Evaluation in Healthy Volunteers: New Generic Formulations of Sitagliptin and Sitagliptin–Metformin Fixed-Dose Combination Compared with the Originator Products
por: Schnaars, Yvonne, et al.
Publicado: (2022) -
Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management
por: Das, Sambit, et al.
Publicado: (2021) -
Vildagliptin/metformin: Lactic acidosis and hypoglycaemia: case report
Publicado: (2022) -
Ten Years of Vildagliptin
por: Del Prato, Stefano
Publicado: (2017) -
Surfing the Vildagliptin Tsunami
por: Balachandran, Karthik
Publicado: (2020)